|
Name |
Palmarumycin C15
|
Molecular Formula | C20H16O7 | |
IUPAC Name* |
(1'R,2'R,3'S,5'S,7'R,11'R)-spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,6'-4,12-dioxatetracyclo[5.4.1.01,7.03,5]dodec-9-ene]-2',8',11'-triol
|
|
SMILES |
C1=CC2=C3C(=C1)OC4([C@@H]5[C@@H](O5)[C@H]([C@]67[C@]4(O6)C(C=C[C@H]7O)O)O)OC3=CC=C2
|
|
InChI |
InChI=1S/C20H16O7/c21-12-7-8-13(22)19-18(12,27-19)16(23)15-17(24-15)20(19)25-10-5-1-3-9-4-2-6-11(26-20)14(9)10/h1-8,12-13,15-17,21-23H/t12-,13?,15+,16-,17+,18-,19-/m1/s1
|
|
InChIKey |
XYDXCACUXWHZSX-LYYLEWAKSA-N
|
|
Synonyms |
Palmarumycin C15
|
|
CAS | NA | |
PubChem CID | 11726507 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 368.3 | ALogp: | 0.1 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 104.0 | Aromatic Rings: | 7 |
Heavy Atoms: | 27 | QED Weighted: | 0.463 |
Caco-2 Permeability: | -5.707 | MDCK Permeability: | 0.00003440 |
Pgp-inhibitor: | 0.007 | Pgp-substrate: | 0.695 |
Human Intestinal Absorption (HIA): | 0.456 | 20% Bioavailability (F20%): | 0.251 |
30% Bioavailability (F30%): | 0.849 |
Blood-Brain-Barrier Penetration (BBB): | 0.911 | Plasma Protein Binding (PPB): | 91.69% |
Volume Distribution (VD): | 0.589 | Fu: | 3.42% |
CYP1A2-inhibitor: | 0.054 | CYP1A2-substrate: | 0.122 |
CYP2C19-inhibitor: | 0.04 | CYP2C19-substrate: | 0.377 |
CYP2C9-inhibitor: | 0.06 | CYP2C9-substrate: | 0.069 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.395 |
CYP3A4-inhibitor: | 0.142 | CYP3A4-substrate: | 0.196 |
Clearance (CL): | 9.719 | Half-life (T1/2): | 0.681 |
hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.995 |
Drug-inuced Liver Injury (DILI): | 0.979 | AMES Toxicity: | 0.675 |
Rat Oral Acute Toxicity: | 0.778 | Maximum Recommended Daily Dose: | 0.78 |
Skin Sensitization: | 0.113 | Carcinogencity: | 0.141 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.03 |
Respiratory Toxicity: | 0.959 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003196 | 0.784 | D0Q3VE | 0.227 | ||||
ENC001988 | 0.733 | D08CCE | 0.221 | ||||
ENC001999 | 0.714 | D01TNW | 0.219 | ||||
ENC003239 | 0.663 | D08DFX | 0.213 | ||||
ENC002330 | 0.663 | D06ALD | 0.212 | ||||
ENC003238 | 0.610 | D06TJJ | 0.210 | ||||
ENC003194 | 0.602 | D06BQU | 0.209 | ||||
ENC003197 | 0.570 | D00JRA | 0.204 | ||||
ENC003195 | 0.524 | D0O6IZ | 0.200 | ||||
ENC003442 | 0.500 | D0AZ8C | 0.197 |